{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:08:37Z","timestamp":1744650517010},"reference-count":44,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.09.061","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:19:36Z","timestamp":1698333576000},"page":"7096-7102","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019\u20132023"],"prefix":"10.1016","volume":"41","author":[{"given":"Pasquale","family":"Stefanizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Moscara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.09.061_b0005","unstructured":"European Medicine Agency. Bexsero: EPAR - product information. Amsterdam. 28\/01\/2013. Last updated: 12\/10\/2022."},{"key":"10.1016\/j.vaccine.2023.09.061_b0010","unstructured":"European Medicine Agency. Trumenba: EPAR - product information. Amsterdam. 06\/06\/2017. Last updated: 14\/11\/2022."},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0015","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2041359","article-title":"Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018\u20132020","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.09.061_b0020","unstructured":"Italian Republic. Ministry of Health. Permanent Conference for the relationships among the State, the Regions and Trento and Bolzano\u2019s autonomous provinces. Intesa, ai sensi dell\u2019articolo 8, comma 6, della legge 5 giugno 2003, n. 131, tra il Governo, le regioni e le province autonome di Trento e Bolzano sul documento recante \u201cPiano nazionale prevenzione vaccinale 2017-2019\u201d. General Series\u2019 Official Gazette n. 41, 18 February 2017."},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0025","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/hematology.2020000117","article-title":"Preventing infections in children and adults with asplenia","volume":"2020","author":"Lee","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"issue":"2","key":"10.1016\/j.vaccine.2023.09.061_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"52","key":"10.1016\/j.vaccine.2023.09.061_b0035","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.vaccine.2019.09.061","article-title":"Vaccination of healthcare personnel in Europe: update to current policies","volume":"37","author":"Maltezou","year":"2019","journal-title":"Vaccine"},{"issue":"7218","key":"10.1016\/j.vaccine.2023.09.061_b0040","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/bmj.319.7218.1147","article-title":"Meningococcal disease and healthcare workers","volume":"319","author":"Pollard","year":"1999","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2023.09.061_b0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"J Am Med Assoc"},{"issue":"9869","key":"10.1016\/j.vaccine.2023.09.061_b0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2023.09.061_b0055","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"33","key":"10.1016\/j.vaccine.2023.09.061_b0060","first-page":"154","article-title":"Systematic use of causality assessment in AEFI surveillance: a 2013\u20132016 pilot study in Puglia","volume":"12","author":"Stefanizzi","year":"2017","journal-title":"EBMJ"},{"key":"10.1016\/j.vaccine.2023.09.061_b0065","unstructured":"Italian Republic. Ministry of Health. Decreto 30 april 2015. Procedure operative e soluzioni tecniche per un\u2019efficace azione di farmacovigilanza adottate ai sensi del comma 344 dell\u2019articolo 1 della legge 24 dicembre 2012, n. 228 (Legge di stabilit\u00e0 2013). General Series\u2019 Official Gazette n. 143, June 23rd, 2015."},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2011652","article-title":"Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014\u201319","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2023.09.061_b0075","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/INF.0000000000002507","article-title":"Prophylactic paracetamol after meningococcal B vaccination reduces postvaccination fever and septic screens in hospitalized preterm infants","volume":"39","author":"Dubus","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.09.061_b0085","unstructured":"UK Health Security Agency. Guidance \u2013 MenB vaccine and paracetamol. Information about the meningococcal B (MenB) vaccine and paracetamol use. Published July 22nd, 2015. Last updated November 24th, 2022. Available online at https:\/\/www.gov.uk\/government\/publications\/menb-vaccine-and-paracetamol. Last accessed on July 20th, 2023."},{"key":"10.1016\/j.vaccine.2023.09.061_b0090","unstructured":"Government of South Australia. SA Health. Meningococcal B Immunisation Program. Last updated on July 6th, 2023. Available online at https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/public+content\/sa+health+internet\/conditions\/immunisation\/immunisation+programs\/meningococcal+b+immunisation+program. Last accessed on July 20th, 2023."},{"key":"10.1016\/j.vaccine.2023.09.061_b0095","unstructured":"Italian National Statistics Institute. Demografics. Available online at https:\/\/demo.istat.it\/. Last accessed on July 18th, 2023."},{"key":"10.1016\/j.vaccine.2023.09.061_b0100","unstructured":"World Health Organization. Global manual on surveillance of adverse events following immunization. Geneva. 2014. Revised March 2016."},{"key":"10.1016\/j.vaccine.2023.09.061_b0105","unstructured":"European Medicines Agency. Inclusion\/exclusion criteria for the \u201cImportant Medical Events\u201d list. Amsterdam. 18 March 2021."},{"key":"#cr-split#-10.1016\/j.vaccine.2023.09.061_b0110.1","unstructured":"Italian Republic. Decreto Legislativo 30 giugno 2003, n. 196. Codice in materia di protezione dei dati personali, ((recante disposizioni per l'adeguamento dell'ordinamento nazionale al regolamento"},{"key":"#cr-split#-10.1016\/j.vaccine.2023.09.061_b0110.2","unstructured":"(UE) n. 2016\/679 del Parlamento europeo e del Consiglio, del 27 aprile 2016, relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali, nonch\u00e9 alla libera circolazione di tali dati e che abroga la direttiva 95\/46\/CE)). General Series' Official Gazette n. 174, July 29th, 2003 - Ordinary Supplement n. 123."},{"issue":"8","key":"10.1016\/j.vaccine.2023.09.061_b0115","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2018.01.018","article-title":"Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy)","volume":"36","author":"Tafuri","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.061_b0120","unstructured":"World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update. Geneva. 2019. License: CC BY-NC-SA 3.0 IGO."},{"issue":"17","key":"10.1016\/j.vaccine.2023.09.061_b0125","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.17.17-00468","article-title":"Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016","volume":"23","author":"Mentzer","year":"2018","journal-title":"Eurosurveillance"},{"issue":"14","key":"10.1016\/j.vaccine.2023.09.061_b0130","article-title":"Allergic adverse events following immunization: data from post-marketing surveillance in Apulia region (South of Italy)","volume":"27","author":"Stefanizzi","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.09.061_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247446","article-title":"Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019","volume":"16","author":"Leitzen","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/14760584.2023.2222015","article-title":"A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)","volume":"22","author":"Marshall","year":"2023","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2023.09.061_b0145","doi-asserted-by":"crossref","first-page":"F171","DOI":"10.1136\/archdischild-2017-314152","article-title":"Safety of meningococcal group B vaccination in hospitalised premature infants","volume":"104","author":"Kent","year":"2019","journal-title":"Arch Dis Childhood-Fetal Neonatal Ed"},{"issue":"52","key":"10.1016\/j.vaccine.2023.09.061_b0150","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1016\/j.vaccine.2018.10.095","article-title":"Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada","volume":"36","author":"De Serres","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2023.09.061_b0155","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/21645515.2017.1287642","article-title":"Hypotonic-hyporesponsive episodes after administration of hexavalent DTP-based combination vaccine: a description of 12 cases","volume":"13","author":"Vigo","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2023.09.061_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050456","article-title":"Post-marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an Italian prospective observational study","volume":"9","author":"Stefanizzi","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0253-7613.150344","article-title":"Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India","volume":"47","author":"Tandon","year":"2015","journal-title":"Indian J Pharmacol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.09.061_b0170","article-title":"Adverse events following measles-mumps-rubella-varicella vaccination and the case of seizures: a post marketing active surveillance in Puglia Italian Region, 2017\u20132018","volume":"7","author":"Stefanizzi","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2023.09.061_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010101","article-title":"Causality assessment guidelines for adverse events following immunization with a focus on Guillain-Barr\u00e9 syndrome","volume":"8","author":"Lee","year":"2020","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2023.09.061_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.516","article-title":"Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review","volume":"5","author":"SeyedAlinaghi","year":"2022","journal-title":"Health Sci Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2023.09.061_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10071030","article-title":"Ten actions to counteract vaccine hesitancy suggested by the Italian Society of Hygiene, Preventive Medicine, and Public Health","volume":"10","author":"Costantino","year":"2022","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2023.09.061_b0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/QCO.0000000000000774","article-title":"Parental vaccine hesitancy: scope, causes, and potential responses","volume":"34","author":"Cataldi","year":"2021","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2023.09.061_b0195","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1080\/21645515.2019.1599675","article-title":"Countering vaccine hesitancy through immunization information systems, a narrative review","volume":"15","author":"Gianfredi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.vaccine.2023.09.061_b0200","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/jan.15222","article-title":"A large cross-sectional survey of COVID-19 vaccination willingness amongst healthcare students and professionals: reveals generational patterns","volume":"78","author":"Tomietto","year":"2022","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.vaccine.2023.09.061_b0205","article-title":"Vaccination programs for children aged up to 18 years in Europe, 2020","author":"Effraimidou","year":"2021","journal-title":"J Child Health Care."},{"issue":"38","key":"10.1016\/j.vaccine.2023.09.061_bib206","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1016\/j.vaccine.2023.07.043","article-title":"Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study","volume":"41","author":"Moscara","year":"2023","journal-title":"Vaccine."},{"issue":"9","key":"10.1016\/j.vaccine.2023.09.061_bib207","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/14760584.2022.2093723","article-title":"COVID-19 vaccination hesitancy in Italian healthcare workers: a systematic review and meta-analysis","volume":"21","author":"Bianchi","year":"2022","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:09:17Z","timestamp":1720037357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011581"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019\u20132023","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}